Agreements reached under this partnership
Business Alliances- 1
Research and development collaboration with Centessa
- 2
The company continues to retain the milestones and royalties related to the future development and commercialization of the program
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
The company will receive US$8.6 million (approximately ¥1,380 million), and the full milestone payment will be recognized as revenue in the third quarter of the fiscal year ending December 2026. The impact on the company's consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the fiscal year disclosed on 13 February 2026.
| Item | Details |
|---|---|
| Name of alliance partner | Centessa Pharmaceuticals Limited (Centessa) |
| Alliance partner's business activities | Centessa's OX2R agonist program, designed to treat a broad range of diseases related to sleep and wakefulness, among others |
| Type of alliance | Business Alliances |
| Details of the alliance | Research and development collaboration with Centessa, The company continues to retain the milestones and royalties related to the future development and commercialization of the program |
| Impact on Business Performance | The company will receive US$8.6 million (approximately ¥1,380 million), and the full milestone payment will be recognized as revenue in the third quarter of the fiscal year ending December 2026. The impact on the company's consolidated results for the fiscal year ending December 2026 has already been incorporated into the consolidated earnings forecast for the fiscal year disclosed on 13 February 2026. |
Items this document does not state (18)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Centessa achieved a late-stage development milestone for its selective orexin 2 receptor (OX2R) agonist under development.